STOCKHOLM, Nov. 8, 2025 /PRNewswire/ — Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe […]
Tag: Swedish Orphan Biovitrum AB
Clinically meaningful pivotal study results for olezarsen in sHTG presented as a late breaker at AHA Scientific Sessions
STOCKHOLM, Nov. 8, 2025 /PRNewswire/ — Sobi® (STO: SOBI) today announced that, the TIMI Study Group today has presented positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe […]
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
STOCKHOLM, Oct. 20, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025 Total revenue increased 13 per cent, 21 per cent at constant […]
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
STOCKHOLM, Oct. 20, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025 Total revenue increased 13 per cent, 21 per cent at constant […]
Sobi Q3 2025 report: Accelerated growth and portfolio momentum
STOCKHOLM, Oct. 20, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025 Third Quarter 2025 Total revenue increased 13 per cent, 21 per cent at constant […]
